
Publication
Strategic asset search and evaluation in biopharma
Biotechnology companies are primarily built around platform technologies and focused on asset specific value creation.
Artificial Intelligence may be the hottest two words in business right now and that is as true in law, litigation and discovery as well.
While there may be more hype than substance at the moment, it is clear that the possibilities of using Generative AI in e-discovery to understand your own documents and that of your opponents is tantalizing.
Read the entire Law.com article, "Enhancing Protective Orders to Address Generative AI."
Publication
Biotechnology companies are primarily built around platform technologies and focused on asset specific value creation.
Subscribe and stay up to date with the latest legal news, information and events . . .
© Norton Rose Fulbright US LLP 2025